J&J Medical Connect
DARZALEX®

(daratumumab)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

DARZALEX - Use of Lower Infusion Volumes

Last Updated: 10/30/2026

SUMMARY  

  • Johnson & Johnson cannot recommend any practices, procedures, or dosing modifications that deviate from product labeling and are not approved by the regulatory agencies.
  • There are no systematically collected data to support using lower infusion volumes or higher concentrations of daratumumab in patients.
  • There are no systematically collected data on infusion rates of DARZALEX in patients with fluid restriction.  
  • Clinical judgment should be exercised when considering any infusion volume adjustments outside of those listed in the DARZALEX product labeling.
  • Administer DARZALEX infusion intravenously at the appropriate infusion rate. Consider incremental escalation of the infusion rate only in the absence of infusion reactions as defined in Table: Infusion Rates for DARZALEX Administration.1

Infusion Rates for DARZALEX Administration1
 
Dilution volume
Initial rate (first hour)
Rate incrementa
Maximum rate
Week 1 infusion
   Option 1 (Single-dose infusion)
         Week 1 Day 1 (16 mg/kg)
1000 mL
50 mL/hour
50 mL/hour every hour
200 mL/hour
   Option 2 (Split-dose infusion)
         Week 1 Day 1 (8 mg/kg)
500 mL
50 mL/hour
50 mL/hour every hour
200 mL/hour
         Week 1 Day 2 (8 mg/kg)
500 mL
50 mL/hour
50 mL/hour every hour
200 mL/hour
Week 2 (16 mg/kg) infusionb
500 mL
50 mL/hour
50 mL/hour every hour
200 mL/hour
Subsequent (Week 3 onwards, 16 mg/kg) infusionsc
500 mL
100 mL/hour
50 mL/hour every hour
200 mL/hour
aConsider incremental escalation of the infusion rate only in the absence of infusion reactions.
bUse a dilution volume of 500 mL for the 16 mg/kg dose only if there were no infusion reactions the previous week. Otherwise, use a dilution volume of 1000 mL.
cUse a modified initial rate (100 mL/hour) for subsequent infusions (i.e. Week 3 onwards) only if there were no infusion reactions during the previous infusion. Otherwise, continue to use instructions indicated in the table for the Week 2 infusion rate.

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 20 October 2026.

 

References

1 Data on File. Daratumumab Intravenous Formulation CCDS. Janssen Research & Development, LLC. EDMS-ERI-78724630; 2026.  

Would you like to clear and leave your conversation? Message history will be lost.